We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.62 | -1.64% | 97.44 | 98.22 | 97.44 | 97.76 | 1,562,845 | 01:00:00 |
From Apr 2021 to Apr 2024
By Colin Kellaher
Shares of Voyager Therapeutics Inc. jumped 15% in premarket trading Tuesday after the gene-therapy company said it inked a license option agreement potentially worth more than $1.7 billion with Swiss drugmaker Novartis AG.
Cambridge, Mass.-based Voyager said that under the deal, Novartis has the option to license novel adeno-associated virus capsids generated from Voyager's RNA-driven Tracer platform for potential use with three undisclosed central-nervous-system targets, along with options to access capsids for two more targets to be agreed on in the future.
Voyager said it will receive an upfront payment of $54 million and will be eligible for up to $1.7 billion in option exercise fees and milestone payments, along with sales-based royalties.
The company last year signed a similar agreement with Pfizer Inc. targeting neurologic and cardiovascular diseases.
Shares of Voyager, which closed Monday at $3.93, were recently up 15% to $4.52 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 08, 2022 06:19 ET (11:19 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
